Radiopharm Theranostics Ltd (RADX) Accounts Payables (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Accounts Payables of $59822.8 for Q2 2025, down 16.39% year-over-year from $71548.9 in Q2 2024, and down 16.39% quarter-over-quarter from $71548.9 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Accounts Payables (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Accounts Payables for 3 consecutive years, with $59822.8 the latest figure, recorded in Q2 2025.
- In Q2 2025, Accounts Payables fell 16.39% year-over-year to $59822.8; the TTM figure through Jun 2025 stood at $59822.8 (down 16.39% YoY), while the FY2025 annual figure was $9.3 million, down 13.96% from the prior year.
- Accounts Payables retreated to $59822.8 in Q2 2025 per RADX's latest filing, from $71548.9 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.1 million in Q2 2023 and bottomed at $59822.8 in Q2 2025.
- Historically, Accounts Payables has averaged $1.8 million across 3 years, with a median of $71548.9 in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables tumbled 98.6% — and 2025, when it declined 16.39%.
- Radiopharm Theranostics' Accounts Payables stood at $5.1 million in 2023, then sank by 98.6% to $71548.9 in 2024, then slipped by 16.39% to $59822.8 in 2025.
- Business Quant data shows RADX's Accounts Payables at $59822.8 in Q2 2025, $71548.9 in Q2 2024, and $5.1 million in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 59,822.82 |
| Jun 30, 2024 | 71,548.92 |
| Jun 30, 2023 | 5.12 Mn |